[Evaluation of the effectiveness of gastro-protected proteoferrin in the therapy of sideropenic anemia in childhood].
The clinical efficacy and tolerability of gastroprotected ferritin were assessed in children affected by iron deficiency and/or sideropenic anemia. Forty-seven children with iron-deficiency and/or sideropenic anemia were included in the study and were treated with gastroprotected ferritin at a dose of 4-5 mg/kg/day per os for 4 months. Only 33 children correctly completed the entire treatment cycle, achieving a marked improvement of blood parameters (increased Hb, accompanied by higher levels of sideremia and in particular ferritin, with a contemporary decrease in erythrocytic protoporphyrin and transferrinemia) and clinical symptoms, especially pallor, anorexia, debility, somnolence, hyperactivity, disturbed sleep and excessive sweating. Of the remaining 14 children, 9 failed to present for the planned control after the 4 months of therapy, 3 abandoned therapy due to difficulties of assumption and 2 because of intolerance phenomena, such as nausea and diarrhoea. In conclusion, gastroprotected proteoferrin is efficacious and well tolerated in the treatment of iron deficiency in children.
Burattini
M G
MG
Istituto di Pediatria Clinica e Preventiva, Università di Bari.
Amendola
F
F
Aufiero
T
T
Spano
M
M
Di Bitonto
G
G
Del Vecchio
G C
GC
De Mattia
D
D
D000747:Anemia, Hypochromic / Q000097:blood / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D005293:Ferritins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000097:blood
D005293:Ferritins; D007501:Iron
Valutazione dell'efficacia della proteoferrina gastroprotetta nella terapia dell'anemia sideropenica in età pediatrica.